MX2012012119A - Produccion de proteinas heteromultimericas. - Google Patents
Produccion de proteinas heteromultimericas.Info
- Publication number
- MX2012012119A MX2012012119A MX2012012119A MX2012012119A MX2012012119A MX 2012012119 A MX2012012119 A MX 2012012119A MX 2012012119 A MX2012012119 A MX 2012012119A MX 2012012119 A MX2012012119 A MX 2012012119A MX 2012012119 A MX2012012119 A MX 2012012119A
- Authority
- MX
- Mexico
- Prior art keywords
- heteromultimeric proteins
- methods
- production
- antibodies
- heteromultimeric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
En la presente se describen métodos para la producción eficiente de anticuerpos y otros complejos de proteínas multiméricas (a los que se hace referencia en conjunto en la presente como proteínas heteromultiméricas) capaces de unirse específicamente a más de un blanco. Los blancos pueden ser, por ejemplo, diferentes epítopos en una sola molécula o ubicados en diferentes moléculas. Los métodos combinan nivel de expresión génica alto eficiente, ensamblaje adecuado, y facilidad de purificación para las proteínas heteromultiméricas. La invención además proporciona método de uso de estas proteínas heteromultiméricas, y composiciones, kits y artículos de producción que comprenden estos anticuerpos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32730210P | 2010-04-23 | 2010-04-23 | |
PCT/US2011/033610 WO2011133886A2 (en) | 2010-04-23 | 2011-04-22 | Production of heteromultimeric proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012012119A true MX2012012119A (es) | 2012-12-17 |
MX346731B MX346731B (es) | 2017-03-30 |
Family
ID=44121029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012012119A MX346731B (es) | 2010-04-23 | 2011-04-22 | Producción de proteínas heteromultiméricas. |
Country Status (15)
Country | Link |
---|---|
US (5) | US9637557B2 (es) |
EP (1) | EP2560683B2 (es) |
JP (2) | JP6048972B2 (es) |
KR (2) | KR101860963B1 (es) |
CN (2) | CN102946906B (es) |
AR (2) | AR080942A1 (es) |
BR (1) | BR112012027001A2 (es) |
CA (1) | CA2796633C (es) |
DK (1) | DK2560683T4 (es) |
ES (1) | ES2617777T5 (es) |
HK (2) | HK1182624A1 (es) |
MX (1) | MX346731B (es) |
RU (1) | RU2624027C2 (es) |
TW (2) | TWI586806B (es) |
WO (1) | WO2011133886A2 (es) |
Families Citing this family (272)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
WO2007114325A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 二重特異性抗体を精製するための抗体改変方法 |
KR101463631B1 (ko) | 2006-03-31 | 2014-11-19 | 추가이 세이야쿠 가부시키가이샤 | 항체의 혈중 동태를 제어하는 방법 |
ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
RU2526512C2 (ru) | 2007-09-26 | 2014-08-20 | Чугаи Сейяку Кабусики Кайся | Модифицированная константная область антитела |
WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
TWI646193B (zh) | 2009-03-19 | 2019-01-01 | 中外製藥股份有限公司 | 抗體恆定區域改變體 |
BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
JP6048972B2 (ja) * | 2010-04-23 | 2016-12-21 | ジェネンテック, インコーポレイテッド | ヘテロ多量体タンパク質の産生 |
JP5953303B2 (ja) | 2010-07-29 | 2016-07-20 | ゼンコア インコーポレイテッド | 改変された等電点を有する抗体 |
RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
DK2644698T3 (en) | 2010-11-17 | 2018-01-22 | Chugai Pharmaceutical Co Ltd | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE WITH ALTERNATIVE FUNCTION TO BLOOD COAGULATION FACTOR FUNCTION VIII |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
EP2756080B1 (en) | 2011-09-14 | 2019-02-20 | Translate Bio MA, Inc. | Multimeric oligonucleotide compounds |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
WO2013055958A1 (en) | 2011-10-11 | 2013-04-18 | Genentech, Inc. | Improved assembly of bispecific antibodies |
CN110964115B (zh) | 2011-10-27 | 2024-03-12 | 健玛保 | 异二聚体蛋白的生成 |
CA2853230C (en) | 2011-10-31 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
CN104080811B (zh) | 2011-11-04 | 2019-09-27 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
SG11201402485UA (en) | 2011-11-21 | 2014-06-27 | Genentech Inc | Purification of anti-c-met antibodies |
PT2794905T (pt) * | 2011-12-20 | 2020-06-30 | Medimmune Llc | Polipéptidos modificados para estrutura de anticorpos bispecíficos |
SG11201403437TA (en) * | 2011-12-22 | 2014-07-30 | Genentech Inc | Ion exchange membrane chromatography |
CA2861124A1 (en) * | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
CN104583239B (zh) * | 2012-05-10 | 2018-09-18 | 生物蛋白有限公司 | 多特异单克隆抗体 |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
KR20150013188A (ko) * | 2012-05-24 | 2015-02-04 | 에프. 호프만-라 로슈 아게 | 다중특이적 항체 |
WO2013187495A1 (ja) | 2012-06-14 | 2013-12-19 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
US9499634B2 (en) | 2012-06-25 | 2016-11-22 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
CN104411718B (zh) | 2012-06-27 | 2018-04-24 | 弗·哈夫曼-拉罗切有限公司 | 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途 |
MX354862B (es) | 2012-06-27 | 2018-03-23 | Hoffmann La Roche | Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes. |
WO2014012082A2 (en) * | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design an constructs |
EP2872170A4 (en) * | 2012-07-13 | 2016-06-22 | Zymeworks Inc | BISPECIFIC ASYMMETRIC HETÉRODIMÈRES COMPRISING ANTI-CD3 RECOMBINANT PRODUCTS |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9206390B2 (en) | 2012-09-02 | 2015-12-08 | Abbvie, Inc. | Methods to control protein heterogeneity |
CN104797933A (zh) | 2012-09-07 | 2015-07-22 | 阿尔伯达大学董事会 | 用于诊断发炎性肝病的方法和组合物 |
AU2013315225B2 (en) * | 2012-09-14 | 2018-11-08 | Translate Bio Ma, Inc. | Multimeric oligonucleotide compounds |
KR20140036905A (ko) * | 2012-09-18 | 2014-03-26 | 삼성전자주식회사 | 이중특이 항체를 포함하는 단백질 복합체 |
US9695228B2 (en) * | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
CA2893562C (en) | 2012-11-28 | 2023-09-12 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
WO2014103847A1 (ja) * | 2012-12-27 | 2014-07-03 | スパイバー株式会社 | 親水性組換えタンパク質の粗精製方法 |
EP2940032B1 (en) * | 2012-12-27 | 2018-04-25 | Spiber Inc. | Extraction method for hydrophilic recombinant protein |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP2951209A4 (en) * | 2013-01-31 | 2016-06-22 | Univ Jefferson | CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF |
SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
EP3839044A1 (en) * | 2013-03-14 | 2021-06-23 | MacroGenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
EP2970422B1 (en) | 2013-03-15 | 2018-04-18 | F.Hoffmann-La Roche Ag | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
KR102049990B1 (ko) * | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
CN105307676A (zh) * | 2013-04-05 | 2016-02-03 | 豪夫迈·罗氏有限公司 | 抗il-4抗体和双特异性抗体及其用途 |
EP2990413B1 (en) | 2013-04-25 | 2019-05-29 | Spiber Inc. | Polypeptide porous body and method for producing same |
EP2990062B1 (en) | 2013-04-25 | 2021-11-10 | Spiber Inc. | Polypeptide hydrogel and method for producing same |
WO2014193973A2 (en) * | 2013-05-28 | 2014-12-04 | Dcb-Usa Llc | Antibody locker for the inactivation of protein drug |
US9879081B2 (en) * | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
US10370776B2 (en) * | 2013-09-25 | 2019-08-06 | Idea Orchard, Llc | Antibody like protein |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
EP3050896B1 (en) * | 2013-09-27 | 2021-07-07 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
JP6585040B2 (ja) | 2013-10-14 | 2019-10-02 | ヤンセン バイオテツク,インコーポレーテツド | システイン改変フィブロネクチンiii型ドメイン結合分子 |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
AU2014347565B2 (en) | 2013-11-11 | 2020-08-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified antibody variable region |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
CN105980409B (zh) | 2013-11-27 | 2023-07-18 | 酵活生物制药有限公司 | 靶向her2的双特异性抗原结合构建体 |
TW201609805A (zh) * | 2013-12-23 | 2016-03-16 | 美國禮來大藥廠 | 結合egfr及met之多功能抗體 |
KR102194142B1 (ko) * | 2014-01-20 | 2020-12-23 | 삼성전자주식회사 | 항 c-Met/항 EGFR 이중 특이 항체 및 c-Src 저해제를 포함하는 병용 투여용 약학 조성물 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
DK3105250T3 (da) * | 2014-02-10 | 2020-09-28 | Igm Biosciences Inc | Multispecifikke iga-bindingsmolekyler |
SG11201606870XA (en) | 2014-02-21 | 2016-09-29 | Genentech Inc | Anti-il-13/il-17 bispecific antibodies and uses thereof |
AU2015237184B2 (en) | 2014-03-28 | 2020-11-26 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
RU2722788C2 (ru) | 2014-04-07 | 2020-06-03 | Чугаи Сейяку Кабусики Кайся | Иммуноактивирующая антигенсвязывающая молекула |
KR20230164192A (ko) | 2014-05-06 | 2023-12-01 | 제넨테크, 인크. | 포유동물 세포를 사용한 이종다량체 단백질의 생산 |
MX2016014434A (es) | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
KR102493430B1 (ko) | 2014-05-28 | 2023-01-31 | 자임워크스 비씨 인코포레이티드 | 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도 |
JP6685934B2 (ja) | 2014-05-29 | 2020-04-22 | マクロジェニクス,インコーポレーテッド | 複数の癌抗原に特異的に結合する三重特異性結合分子及びその使用方法 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
JP6702893B2 (ja) * | 2014-06-27 | 2020-06-03 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的抗原結合タンパク質 |
JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的NKp46結合タンパク質 |
US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
KR101940430B1 (ko) * | 2014-08-07 | 2019-01-18 | 가꼬우호우징 효고 이카다이가쿠 | Il-18과 분자 표적 항체를 병용하는 암 치료약 |
KR20170052600A (ko) | 2014-09-12 | 2017-05-12 | 제넨테크, 인크. | 시스테인 가공된 항체 및 콘주게이트 |
MY186334A (en) | 2014-09-12 | 2021-07-12 | Genentech Inc | Anti-her2 antibodies and immunoconjugates |
WO2016040868A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
WO2016040892A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies |
CA2957148A1 (en) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
ES2935062T3 (es) | 2014-09-26 | 2023-03-01 | Macrogenics Inc | Diacuerpos monovalentes biespecíficos que son capaces de unirse a CD19 y CD3 y usos de los mismos |
AU2015342961B2 (en) | 2014-11-05 | 2021-08-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
ES2819256T3 (es) | 2014-11-05 | 2021-04-15 | Genentech Inc | Métodos para producir proteínas bicatenarias en bacterias |
JP6929771B2 (ja) | 2014-11-10 | 2021-09-01 | ジェネンテック, インコーポレイテッド | 抗インターロイキン−33抗体及びその使用 |
WO2016076345A1 (ja) | 2014-11-11 | 2016-05-19 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子のライブラリ |
US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
JP6993228B2 (ja) | 2014-11-19 | 2022-03-03 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法 |
CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
MY184268A (en) | 2014-11-26 | 2021-03-30 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
SG11201703750XA (en) | 2014-12-10 | 2017-06-29 | Genentech Inc | Blood brain barrier receptor antibodies and methods of use |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
KR20170105622A (ko) | 2015-01-26 | 2017-09-19 | 마크로제닉스, 인크. | Dr5-결합 도메인을 포함하는 다가 분자 |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
EP3277821B1 (en) * | 2015-03-31 | 2019-07-24 | NovImmune SA | Method for optimizing the assembly and production of hetero-multimeric protein complexes |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
KR20170132793A (ko) | 2015-04-03 | 2017-12-04 | 유레카 쎄라퓨틱스, 인코포레이티드 | Afp 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도 |
US10787500B2 (en) * | 2015-04-10 | 2020-09-29 | Adimab, Llc | Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species |
GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
CN114652827A (zh) | 2015-05-29 | 2022-06-24 | 安普希韦纳治疗公司 | 双特异性cd33和cd3结合蛋白质的使用方法 |
KR102141446B1 (ko) | 2015-06-04 | 2020-08-06 | 오스페달레 산 라파엘 에스.알.엘. | Igfbp3 및 이의 용도 |
BR112017025998A2 (pt) | 2015-06-04 | 2018-08-14 | Ospedale San Raffaele Srl | inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
JP6840682B2 (ja) * | 2015-06-23 | 2021-03-10 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的抗原結合タンパク質 |
AU2016284871B2 (en) | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
PL3328419T3 (pl) | 2015-07-30 | 2021-12-27 | Macrogenics, Inc. | Cząsteczki wiążące pd-1 i sposoby ich zastosowania |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
RU2018116846A (ru) | 2015-10-08 | 2019-11-08 | Займворкс Инк. | Антигенсвязывающие полипептидные конструкции, содержащие легкие цепи каппа и лямбда, и их применения |
WO2017062619A2 (en) | 2015-10-08 | 2017-04-13 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
JP6998869B2 (ja) | 2015-11-08 | 2022-02-04 | ジェネンテック, インコーポレイテッド | 多重特異性抗体のスクリーニング方法 |
EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE |
US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
AR107781A1 (es) | 2015-12-14 | 2018-06-06 | Macrogenics Inc | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION |
MX2018008063A (es) | 2015-12-30 | 2018-11-29 | Genentech Inc | Uso de derivados de triptofano para formulaciones de proteina. |
WO2017117311A1 (en) | 2015-12-30 | 2017-07-06 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
US20170233472A1 (en) | 2016-02-17 | 2017-08-17 | Macrogenics, Inc. | ROR1-Binding Molecules, and Methods of Use Thereof |
EP3431102A4 (en) | 2016-03-14 | 2019-09-25 | Chugai Seiyaku Kabushiki Kaisha | THERAPEUTIC MEDICINE INDUCING CELLULAR INJURY FOR USE IN THE TREATMENT OF CANCER |
CN110088126A (zh) | 2016-04-15 | 2019-08-02 | 高山免疫科学股份有限公司 | Icos配体变体免疫调节蛋白及其用途 |
GEP20227398B (en) | 2016-04-15 | 2022-07-25 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof |
MA43552A (fr) | 2016-04-15 | 2018-11-07 | Alpine Immune Sciences Inc | Protéines immunomodulatrices à variants de cd80 et leurs utilisations |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US11753438B2 (en) | 2016-05-11 | 2023-09-12 | Cytiva Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
US20170370906A1 (en) | 2016-05-27 | 2017-12-28 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
JP6843891B2 (ja) | 2016-06-02 | 2021-03-17 | アッヴィ・インコーポレイテッド | グルココルチコイド受容体アゴニスト及びこのイムノコンジュゲート |
CN109476648B (zh) | 2016-06-06 | 2022-09-13 | 豪夫迈·罗氏有限公司 | 司维司群抗体-药物缀合物和使用方法 |
EP4257613A3 (en) | 2016-06-14 | 2023-12-13 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
MX2018015173A (es) | 2016-06-17 | 2019-07-04 | Genentech Inc | Purificacion de anticuerpos multiespecificos. |
EP3471750A4 (en) | 2016-06-21 | 2020-02-26 | Janssen Biotech, Inc. | CYSTEINE-MODIFIED TYPE III FIBRONECTIN BINDING MOLECULES |
JP7021127B2 (ja) | 2016-06-28 | 2022-02-16 | ゼンコア インコーポレイテッド | ソマトスタチン受容体2に結合するヘテロ二量体抗体 |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
US10696722B2 (en) | 2016-08-10 | 2020-06-30 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
EP3496763A1 (en) | 2016-08-11 | 2019-06-19 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CN110139674B (zh) | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 制备抗体药物缀合物的方法 |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
WO2018071919A1 (en) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS |
CR20190297A (es) | 2016-11-23 | 2019-11-01 | Bioverativ Therapeutics Inc | Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x |
US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
WO2018111973A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd8a-binding fibronectin type iii domains |
US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
CA3048211A1 (en) | 2016-12-23 | 2018-06-28 | Macrogenics, Inc. | Adam9-binding molecules, and methods of use thereof |
WO2018126232A1 (en) * | 2016-12-29 | 2018-07-05 | Development Center For Biotechnology | Klk6-mediated cns-specific antibody prodrug activation |
WO2018132597A1 (en) | 2017-01-12 | 2018-07-19 | Eureka Therapeutics, Inc. | Constructs targeting histone h3 peptide/mhc complexes and uses thereof |
MX2019009485A (es) | 2017-02-10 | 2019-11-05 | Genentech Inc | Anticuerpos contra triptasa, composiciones de estos y usos de estos. |
JP7132232B2 (ja) | 2017-02-24 | 2022-09-06 | マクロジェニクス,インコーポレーテッド | Cd137及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 |
MX2019010887A (es) | 2017-03-16 | 2019-10-15 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de cb80 variante y usos de estas. |
EP3596116B1 (en) | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
WO2018170023A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
CA3059820A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
CN108866635B (zh) | 2017-05-09 | 2021-11-26 | 安升(上海)医药科技有限公司 | 多特异性蛋白药物及其文库、以及制备方法和应用 |
EP3645122A1 (en) | 2017-06-30 | 2020-05-06 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
MA50360A (fr) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences Inc | Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations |
MX2020004540A (es) | 2017-10-18 | 2020-08-03 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados. |
BR112020007154A2 (pt) | 2017-10-20 | 2020-09-29 | F. Hoffmann-La Roche Ag | método para produzir um polipeptídeo e polipeptídeos heterodimérico |
WO2019084165A1 (en) * | 2017-10-27 | 2019-05-02 | 10X Genomics, Inc. | METHODS AND SYSTEMS FOR SAMPLE PREPARATION AND ANALYSIS |
EP3704145A1 (en) | 2017-10-30 | 2020-09-09 | F. Hoffmann-La Roche AG | Method for in vivo generation of multispecific antibodies from monospecific antibodies |
US11339221B2 (en) | 2017-11-01 | 2022-05-24 | Tufts Medical Center, Inc. | Bispecific antibody constructs and methods of use |
CA3082383A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
MX2020005583A (es) | 2017-12-01 | 2020-11-25 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados de este. |
JP7357616B2 (ja) | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子 |
KR20200098590A (ko) | 2017-12-12 | 2020-08-20 | 마크로제닉스, 인크. | 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도 |
KR20200100098A (ko) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
CN117050184A (zh) | 2017-12-28 | 2023-11-14 | 南京传奇生物科技有限公司 | 针对tigit的单域抗体和其变体 |
JP7366908B2 (ja) | 2018-01-15 | 2023-10-23 | ナンジン レジェンド バイオテック カンパニー,リミテッド | Pd-1に対する単一ドメイン抗体及びその変異体 |
CN111655717A (zh) | 2018-01-26 | 2020-09-11 | 豪夫迈·罗氏有限公司 | IL-22 Fc融合蛋白及使用方法 |
PT3743088T (pt) | 2018-01-26 | 2022-12-05 | Hoffmann La Roche | Composições il-22 fc e métodos de utilização |
EA202091689A1 (ru) * | 2018-01-31 | 2020-10-22 | Ридженерон Фармасьютикалз, Инк. | Система и способ определения характеристик примесей, представляющих собой варианты, отличающиеся по размеру и заряду, в продукте, представляющем собой лекарственное средство |
MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
CN111787947A (zh) | 2018-02-09 | 2020-10-16 | 豪夫迈·罗氏有限公司 | 用于肥大细胞介导的炎性疾病的治疗和诊断方法 |
CN111787949A (zh) | 2018-02-15 | 2020-10-16 | 宏观基因有限公司 | 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途 |
EP3755364A1 (en) | 2018-02-21 | 2020-12-30 | F. Hoffmann-La Roche AG | Dosing for treatment with il-22 fc fusion proteins |
WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
EP3781599A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
CN110386978A (zh) * | 2018-04-19 | 2019-10-29 | 上海多米瑞生物技术有限公司 | 大肠杆菌周质空间表达的蛋白的提取方法 |
US20210363219A1 (en) | 2018-06-15 | 2021-11-25 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
AR115925A1 (es) | 2018-08-08 | 2021-03-10 | Genentech Inc | Uso de derivados de triptófano y l-metionina para formulación de proteínas |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
MA53822A (fr) | 2018-10-03 | 2021-08-11 | Xencor Inc | Protéines de fusion fc hétérodimères d'il -12 |
EP3864049A1 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
CN113518647A (zh) | 2018-10-11 | 2021-10-19 | 印希比股份有限公司 | 5t4单域抗体及其治疗性组合物 |
CA3115082A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
US20210380679A1 (en) | 2018-10-11 | 2021-12-09 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
EP3870598A1 (en) | 2018-10-23 | 2021-09-01 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
EP3870235A1 (en) | 2018-10-24 | 2021-09-01 | F. Hoffmann-La Roche AG | Conjugated chemical inducers of degradation and methods of use |
CN113260626A (zh) | 2018-11-05 | 2021-08-13 | 豪夫迈·罗氏有限公司 | 在原核宿主细胞中产生双链蛋白质的方法 |
CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
CN113227119A (zh) | 2018-12-10 | 2021-08-06 | 基因泰克公司 | 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽 |
CN113329759A (zh) * | 2019-01-07 | 2021-08-31 | 沙塔克实验室有限公司 | 用于调节γδT细胞的异二聚体蛋白 |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
CN114173875A (zh) | 2019-03-01 | 2022-03-11 | Xencor股份有限公司 | 结合enpp3和cd3的异二聚抗体 |
CN110068491A (zh) * | 2019-04-15 | 2019-07-30 | 湖北擎科生物科技有限公司 | 一种高灵敏度低背景考马斯亮蓝染色液及其使用方法 |
US20220324933A1 (en) * | 2019-07-12 | 2022-10-13 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
WO2021011864A1 (en) * | 2019-07-18 | 2021-01-21 | Memorial Sloan Kettering Cancer Center | METHODS AND COMPOSITIONS FOR TARGETING TGF-β SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY |
KR20220041146A (ko) | 2019-07-26 | 2022-03-31 | 제넨테크, 인크. | IL-22 Fc 융합 단백질들을 사용한, 이식편 대 숙주 질환 (GVHD)의 예방 또는 치료를 위한 투약 |
KR20220066295A (ko) | 2019-09-20 | 2022-05-24 | 제넨테크, 인크. | 항트립타제 항체의 투약 |
JP2022551204A (ja) | 2019-10-14 | 2022-12-07 | アロ・バイオセラピューティクス・カンパニー | Cd71結合フィブロネクチンiii型ドメイン |
WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
CN110964119A (zh) * | 2019-12-05 | 2020-04-07 | 沣潮医药科技(上海)有限公司 | 抗疟二聚体免疫粘附素、药物组合物和用途 |
CN115380047A (zh) | 2020-01-29 | 2022-11-22 | 印希比股份有限公司 | Cd28单结构域抗体及其多价和多特异性构建体 |
AU2021225920A1 (en) | 2020-02-28 | 2022-09-15 | Shanghai Henlius Biotech, Inc. | Anti-CD137 construct and use thereof |
BR112022018254A2 (pt) | 2020-03-13 | 2022-10-25 | Genentech Inc | Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo |
PE20230077A1 (es) | 2020-03-31 | 2023-01-11 | Chugai Pharmaceutical Co Ltd | Moleculas de union al antigeno multiespecificas dirigidas a ligando de tipo delta 3 (dll3) y sus usos |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
EP4175650A1 (en) | 2020-07-06 | 2023-05-10 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
AU2021312225A1 (en) | 2020-07-21 | 2023-02-16 | Genentech, Inc. | Antibody-conjugated chemical inducers of degradation of BRM and methods thereof |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
EP4214244A1 (en) | 2020-09-21 | 2023-07-26 | Genentech, Inc. | Purification of multispecific antibodies |
WO2022082217A1 (en) | 2020-10-16 | 2022-04-21 | Eureka Therapeutics, Inc. | Compositions for preventing or treating viral and other microbial infections |
WO2022108627A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
AU2021395729A1 (en) | 2020-12-07 | 2023-07-13 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
TW202304946A (zh) | 2021-03-31 | 2023-02-01 | 瑞士商赫孚孟拉羅股份公司 | 藉由混合模式層析純化抗體 |
WO2023011650A1 (zh) * | 2021-08-06 | 2023-02-09 | 甘李药业股份有限公司 | 一种多特异性抗体及其用途 |
WO2023019239A1 (en) | 2021-08-13 | 2023-02-16 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2023147329A1 (en) | 2022-01-26 | 2023-08-03 | Genentech, Inc. | Antibody-conjugated chemical inducers of degradation and methods thereof |
WO2023147328A1 (en) | 2022-01-26 | 2023-08-03 | Genentech, Inc. | Antibody-conjugated chemical inducers of degradation with hydolysable maleimide linkers and methods thereof |
WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
WO2023230488A1 (en) | 2022-05-23 | 2023-11-30 | Cereius, Inc. | Her2-binding agents and uses thereof |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2415708A1 (fr) | 1978-01-30 | 1979-08-24 | Renault | Dispositif de retenue et de verrouillage pour berceau de roue de secours |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
SE8505922D0 (sv) | 1985-12-13 | 1985-12-13 | Kabigen Ab | Construction of an igg binding protein to facilitate downstream processing using protein engineering |
EP0252962B1 (en) | 1985-12-23 | 1995-08-23 | Fred Hutchinson Cancer Research Center | Regulating retroviral replication, infection, and pathogenesis |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
CA2046909A1 (en) | 1989-03-21 | 1990-09-22 | Mark D. Howell | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ES2112838T5 (es) | 1989-07-19 | 2004-09-01 | Connetics Corporation | Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas. |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CZ283050B6 (cs) | 1989-12-20 | 1997-12-17 | Schering Corporation | Polypeptid, jeho subsekvence a jejich použití |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
CA2097060A1 (en) † | 1990-12-04 | 1992-06-05 | Peter J. Curtis | Bifunctional antibodies and method of preparing same |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
US6129914A (en) * | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
UA40577C2 (uk) * | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
ES2191702T3 (es) | 1994-03-17 | 2003-09-16 | Merck Patent Gmbh | Fv monocatenarios anti-egfr y anticuerpos anti-egfr. |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
WO1997038123A1 (en) | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
DE69934425T2 (de) | 1998-10-23 | 2007-09-27 | Amgen Inc., Thousand Oaks | Thrombopoietin substitute |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
KR100919593B1 (ko) | 2000-06-29 | 2009-09-29 | 아보트 러보러터리즈 | 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물 |
US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
US8372954B2 (en) | 2000-12-22 | 2013-02-12 | National Research Council Of Canada | Phage display libraries of human VH fragments |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
ES2387546T3 (es) | 2001-05-11 | 2012-09-25 | Amgen Inc. | Péptidos y moléculas relacionadas que se unen a TALL-1 |
WO2002100348A2 (en) † | 2001-06-13 | 2002-12-19 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
JP4836451B2 (ja) | 2002-07-18 | 2011-12-14 | メルス ベー ヴェー | 抗体混合物の組換え生産 |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
LT3284753T (lt) † | 2002-10-17 | 2020-06-10 | Genmab A/S | Žmogaus monokloniniai antikūnai prieš cd20, skirti naudoti gydant išsėtinę sklerozę |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
KR20120104408A (ko) | 2003-05-30 | 2012-09-20 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
SI1639011T1 (sl) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
US7472724B2 (en) | 2003-08-18 | 2009-01-06 | Electrolock, Inc. | Method and apparatus for creating, using, and dispensing tubes |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
WO2005062916A2 (en) | 2003-12-22 | 2005-07-14 | Centocor, Inc. | Methods for generating multimeric molecules |
CN104013957B (zh) | 2003-12-23 | 2016-06-29 | 泰勒公司 | 用新的抗il13单克隆抗体治疗癌症 |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
SI1776383T1 (sl) * | 2004-07-22 | 2014-12-31 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
PE20060560A1 (es) | 2004-08-03 | 2006-06-27 | Novartis Ag | Anticuerpos de interleucina-4 humana |
KR101247908B1 (ko) * | 2004-09-02 | 2013-03-26 | 제넨테크, 인크. | 항-fc-감마 riib 수용체 항체 및 그의 용도 |
EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
PT1951759E (pt) | 2005-11-12 | 2010-04-01 | Lilly Co Eli | Anticorpos anti-egfr |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
ES2667863T3 (es) * | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
SG10201605250SA (en) | 2008-10-14 | 2016-08-30 | Genentech Inc | Immunoglobulin variants and uses thereof |
CN102356092B (zh) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
JP6048972B2 (ja) * | 2010-04-23 | 2016-12-21 | ジェネンテック, インコーポレイテッド | ヘテロ多量体タンパク質の産生 |
-
2011
- 2011-04-22 JP JP2013506328A patent/JP6048972B2/ja active Active
- 2011-04-22 KR KR1020127030541A patent/KR101860963B1/ko active IP Right Grant
- 2011-04-22 CA CA2796633A patent/CA2796633C/en active Active
- 2011-04-22 MX MX2012012119A patent/MX346731B/es active IP Right Grant
- 2011-04-22 US US13/092,708 patent/US9637557B2/en active Active
- 2011-04-22 EP EP11718831.8A patent/EP2560683B2/en active Active
- 2011-04-22 BR BR112012027001A patent/BR112012027001A2/pt not_active Application Discontinuation
- 2011-04-22 RU RU2012149858A patent/RU2624027C2/ru active
- 2011-04-22 ES ES11718831T patent/ES2617777T5/es active Active
- 2011-04-22 KR KR1020187013781A patent/KR20180053775A/ko not_active Application Discontinuation
- 2011-04-22 CN CN201180031150.3A patent/CN102946906B/zh active Active
- 2011-04-22 WO PCT/US2011/033610 patent/WO2011133886A2/en active Application Filing
- 2011-04-22 DK DK11718831.8T patent/DK2560683T4/da active
- 2011-04-22 TW TW100114160A patent/TWI586806B/zh active
- 2011-04-22 TW TW106108666A patent/TW201742925A/zh unknown
- 2011-04-22 CN CN201510346609.9A patent/CN105001330B/zh active Active
- 2011-04-25 AR ARP110101404A patent/AR080942A1/es not_active Application Discontinuation
-
2013
- 2013-08-26 HK HK13109967.5A patent/HK1182624A1/xx unknown
-
2016
- 2016-02-25 HK HK16102160.2A patent/HK1214277A1/zh unknown
- 2016-07-21 JP JP2016143078A patent/JP2017061444A/ja active Pending
-
2017
- 2017-10-27 US US15/796,530 patent/US20180282431A1/en not_active Abandoned
-
2018
- 2018-07-25 US US16/045,539 patent/US20190185584A1/en not_active Abandoned
-
2020
- 2020-09-18 US US17/025,980 patent/US20210171662A1/en not_active Abandoned
- 2020-11-19 AR ARP200103212A patent/AR120511A2/es unknown
-
2023
- 2023-04-07 US US18/132,131 patent/US20230357445A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX346731B (es) | Producción de proteínas heteromultiméricas. | |
MX355255B (es) | Variantes de fc y métodos para su producción. | |
MX359384B (es) | Conjunto mejorado de anticuerpos bisespecificos. | |
WO2015051199A3 (en) | Modified pseudomonas exotoxin a | |
MX2021001418A (es) | Produccion de proteinas heteromultimericas usando celulas de mamifero. | |
GB201020995D0 (en) | Biological materials and uses thereof | |
EA201890613A1 (ru) | Полипептиды, связывающие cd3 | |
WO2016094873A3 (en) | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods | |
WO2011106766A3 (en) | Modified proteins and methods of making and using same | |
UA102867C2 (uk) | Антитіла до cxcr4 та їх застосування у лікуванні раку | |
MX350355B (es) | Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a. | |
AU2012257942A8 (en) | Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same | |
BR112014019579A2 (pt) | Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero | |
WO2013138793A3 (en) | Affinity reagants for protein purification | |
MX2007013759A (es) | Agentes de union de esclerostina. | |
NZ592432A (en) | Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1) | |
NZ761636A (en) | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods | |
UA99602C2 (ru) | Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток | |
TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
EA201101516A1 (ru) | Антитела, специфические для кадгерина-17 | |
AU2011353197A8 (en) | A cross linking polypeptide comprising an hexameric single chain antibody binding MHC-MAGE complex that induces apoptosis | |
WO2008087642A3 (en) | Nucleic acid constructs and methods for specific silencing of h19 | |
WO2014151982A3 (en) | Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment | |
WO2011112566A3 (en) | Basigin binding proteins | |
WO2011116212A3 (en) | Bone morphogenetic protein receptor binding agents and methods of their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |